TY - JOUR
T1 - The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs
T2 - From the perspective of a large group of CML experts
AU - Experts in Chronic Myeloid Leukemia
AU - Abboud, Camille
AU - Berman, Ellin
AU - Cohen, Adam
AU - Cortes, Jorge
AU - DeAngelo, Daniel
AU - Deininger, Michael
AU - Devine, Steven
AU - Druker, Brian
AU - Fathi, Amir
AU - Jabbour, Elias
AU - Jagasia, Madan
AU - Kantarjian, Hagop
AU - Khoury, Jean
AU - Laneuville, Pierre
AU - Larson, Richard
AU - Lipton, Jeffrey
AU - Moore, Joseph O.
AU - Mughal, Tariq
AU - O'Brien, Susan
AU - Pinilla-Ibarz, Javier
AU - Quintas-Cardama, Alfonso
AU - Radich, Jerald
AU - Reddy, Vishnu
AU - Schiffer, Charles
AU - Shah, Neil
AU - Shami, Paul
AU - Silver, Richard T.
AU - Snyder, David
AU - Stone, Richard
AU - Talpaz, Moshe
AU - Tefferi, Ayalew
AU - Van Etten, Richard A.
AU - Wetzler, Meir
AU - Abruzzese, Elisabetta
AU - Apperley, Jane
AU - Breccia, Massimo
AU - Byrne, Jenny
AU - Cervantes, Francisco
AU - Chelysheva, Ekaterina
AU - Clark, R. E.
AU - De Lavallade, Hugues
AU - Dyagil, Iryna
AU - Gambacorti-Passerini, Carlo
AU - Goldman, John
AU - Haznedaroglu, Ibrahim
AU - Hjorth-Hansen, Henrik
AU - Holyoake, Tessa
AU - Huntly, Brian
AU - Le Coutre, Philipp
AU - Yehuda, Dina Ben
N1 - Publisher Copyright:
© 2013 by The American Society of Hematology.
PY - 2013/5/30
Y1 - 2013/5/30
N2 - As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
AB - As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
UR - http://www.scopus.com/inward/record.url?scp=84880790088&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-03-490003
DO - 10.1182/blood-2013-03-490003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 23620577
AN - SCOPUS:84880790088
SN - 0006-4971
VL - 121
SP - 4439
EP - 4442
JO - Blood
JF - Blood
IS - 22
ER -
